Floatz Rating
BB65/100
Confidence
Indicative
Sponsor
Indapta Therapeutics, INC.
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
50High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06677710CT.gov IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis | — | Suspended | — | — | — |
NCT03696784CT.gov Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma | — | Active Not Recruiting | — | — | — |
NCT03672318CT.gov Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma | — | Active Not Recruiting | — | — | — |
NCT03602157CT.gov Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | — | Active Not Recruiting | — | — | — |
NCT03128996CT.gov Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders | — | Recruiting | — | — | — |
NCT02294552CT.gov Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT | — | Completed | — | — | — |
NCT01821781CT.gov Immune Disorder HSCT Protocol | — | Active Not Recruiting | — | — | — |
NCT01596699CT.gov Pilot Trial of Clofarabine Added to Standard Busulfan and Fludarabine for Conditioning Prior to Allogeneic Hematopoietic Cell Transplantation | — | Terminated | — | — | — |
NCT03016377CT.gov Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL | — | Active Not Recruiting | — | — | — |
NCT03594162CT.gov Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Immune System Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Fludarabine (this asset) | Indapta Therapeutics, INC. | P2 | BB · 65 |
| Cyclophosphamide | Indapta Therapeutics, INC. | P2 | BB |
| Lidocaine | Ciusss de L'Est de l'Île de Montréal | P4 | BB |
| Melphalan | Washington University School of Medicine | P2 | B |
| Alemtuzumab | Washington University School of Medicine | P2 | B |
| Thiotepa | Washington University School of Medicine | P2 | B |
| Ibrutinib | Oncternal Therapeutics, Inc | P3 | B |
| Zilovertamab | Oncternal Therapeutics, Inc | P3 | B |
| Strimvelis | Fondazione Telethon | P4 | B |
+30 more in the Immune System Disorder cohort
Other indications for Fludarabine
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult T-Cell Leukemia/Lymphoma | — | P2 | BBB · 76 |
| Acute Myeloid Leukemia With Abnormal Bone Marrow Eosinophils Inv(16)(P13q22) Or T(16;16)(P13;Q22) | — | P2 | BBB · 76 |
| Fanconi Anemia | — | P2/3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Fludarabine in Immune System Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/fludarabine-immune-system-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →